Drugabilis

Executive Summary

Drugabilis is a French consulting and services firm specializing in pharmaceutical drugability strategy, based in Paris and founded in 2018. The company assists biotech and pharmaceutical clients in optimizing early-stage drug development by clarifying development strategies, prioritizing studies, and de-risking programs. Their expertise enhances project value and R&D efficiency, positioning them as a valuable partner for companies seeking to improve the success of their drug candidates. Despite operating in the competitive drug delivery and consulting space, Drugabilis differentiates through a focused niche on drugability, a critical step in preclinical development. The company is private and pre-clinical stage, with no disclosed funding rounds or valuation, indicating a lean, service-based business model. As a consulting entity, Drugabilis's growth is likely tied to client acquisition and repeat engagements rather than product development milestones. The company's moderate profile suggests steady operations but limited visibility in the broader biotech ecosystem.

Upcoming Catalysts (preview)

• TBDAnnouncement of major partnership or contract with a top-tier pharma company40% success
• Q3 2026Expansion of service offerings into new therapeutic areas or geographies50% success
• TBDPublication of successful case study demonstrating drugability de-risking impact60% success